SCHEMBL3479437

SCHEMBL3479437

CN1CCN(c2cccc(Cl)c2)c2ccc(-c3cncnc3)cc2C1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 1/20 0.43
DRD2 P14416 3/20 0.43
DRD3 P35462 2/20 0.43
KCNH2 Q12809 2/20 0.43
WDR5 P61964 2/20 0.42
KMT2A Q03164 1/20 0.42
GAA P10253 2/20 0.40
LMNA P02545 1/20 0.40
TP53 P04637 1/20 0.39
SLC6A2 P23975 2/20 0.39
SLC6A4 P31645 2/20 0.39
SLC6A3 Q01959 2/20 0.39
FNTA P49354 4/20 0.39
PGGT1B P53609 4/20 0.39
CYP11B1 P15538 1/20 0.38
CYP11B2 P19099 1/20 0.38
HRH4 Q9H3N8 1/20 0.38
DRD4 P21917 1/20 0.38
HTR2A P28223 1/20 0.38
ALDH1A1 P00352 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3231301 0.89 CYP11B1 (0.50) SCN9ADRD2DRD3KCNH2GAA
SCHEMBL3227222 0.88 SCN9A (0.46) SCN9ADRD2DRD3KCNH2WDR5
SCHEMBL3479501 0.87 SLC6A2 (0.45) SCN9ADRD2WDR5KMT2ASLC6A2
SCHEMBL3226224 0.87 SCN9A (0.45) SCN9ADRD2WDR5KMT2ASLC6A2
SCHEMBL3231874 0.87 SCN9A (0.43) SCN9ADRD2DRD3WDR5KMT2A
SCHEMBL3232006 0.85 WDR5 (0.43) SCN9ADRD2DRD3KCNH2WDR5
SCHEMBL3225814 0.83 SCN9A (0.42) SCN9ADRD2WDR5KMT2ASLC6A2
SCHEMBL3479616 0.83 SCN9A (0.44) SCN9ADRD2DRD3KCNH2GAA
SCHEMBL3226298 0.83 SCN9A (0.45) SCN9ADRD2DRD3KCNH2GAA
SCHEMBL3479750 0.82 HTR3A (0.45) SCN9ADRD2WDR5KMT2ASLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096546-B2 Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin ALBANY MOLECULAR RESEARCH, INC. (US) 2015-08-04 US disclosed
US-20100137287-A1 ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN ALBANY MOLECULAR RESEARCH, INC. (US) 2010-06-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137287-A1 ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN ADRA1B, ADRB1, ADRA1D SCN9A 795/4885DRD2 5/4885DRD3 12/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.